Author Login IJIRT Partner Network (IPN) Login

A REVIEW ON METHOD DEVELOPMENT AND VALIDATION OF FAVIPIRAVIR BULK AND THEIR TABLET DOSAGE FORM

  • Unique Paper ID: 158529
  • Volume: 9
  • Issue: 9
  • PageNo: 615-620
  • Abstract:
  • Favipiravir is an antiviral drug that was initially developed for influenza by Toyama Chemical, which has recently garnered much attention, especially in India, is an anti-viral drug originally designed for influenza, called Favipiravir. In this article, we have tried to provide a complete, evidence-based review of this drug in the perspective of the present pandemic to give further details about its role in the management of COVID-19. Favipiravir is a very widely used pharmaceutical, consequently it has been detected in the water system. The aim of this review is to focus on update of determination of Favipiravir in bulk and in pharmaceutical preparations using chromatographic and spectrophotometric methods. Favipiravir are estimated by RP-HPLC, UV, HPLC, RP-HPLC,UPLC, methods. For subjective and quantitative estimation of Favipiravir these diagnostic techniques can be utilized. This review provides detailed information on separation conditions for Favipiravir in the presence of drug and in presence of its degradation products.
Download article email to a friend

Cite This Article

  • ISSN: 2349-6002
  • Volume: 9
  • Issue: 9
  • PageNo: 615-620

A REVIEW ON METHOD DEVELOPMENT AND VALIDATION OF FAVIPIRAVIR BULK AND THEIR TABLET DOSAGE FORM

Related Articles

Impact Factor
8.01 (Year 2024)
UGC Approved
Journal no 47859

Join Our IPN

IJIRT Partner Network

Submit your research paper and those of your network (friends, colleagues, or peers) through your IPN account, and receive 800 INR for each paper that gets published.

Join Now

Latest Publication

Archive

View More

Recent Conferences

NCSEM 2024

National Conference on Sustainable Engineering and Management - 2024 Last Date: 15th March 2024

Submit inquiry